CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $59.75M, above the global median of $18.73M
- FinancialsAltman Z-Score 5.09: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.18%Below 5Y avg (1.09%)
Annual Rate
CNY 0.01Paid annual
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Jul 22, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.77BCNY861.21M · vs all stocks (USD)
Revenue (TTM)
570.26MCNY85.06M · vs all stocks (USD)
Profit Margin
-126.84%Beta
-0.1540xvs all stocks
52-Week Change
-22.70%vs all stocks
Market Capitalization
5.77BCNY861.21M · vs all stocks (USD)
Enterprise Value
4.54BCNY677.87M · vs all stocks (USD)
Price to Sales (TTM)
10.12xPrice to Book (MRQ)
1.17xEnterprise to Revenue
7.97xEnterprise to EBITDA
31.36xGross Margin
63.62%Profit Margin
-126.84%Operating Margin
-30.75%Return on Assets (TTM)
-0.25%Return on Equity (TTM)
-13.63%Revenue (TTM)
570.26MCNY85.06M · vs all stocks (USD)
Revenue per Share (TTM)
0.5550CNYUpdated Sep 19, 2026Quarterly Revenue Growth
-15.70%Gross Profit (TTM)
348.31MCNY51.95M · vs all stocks (USD)
EBITDA (TTM)
458.98MCNY68.46M · vs all stocks (USD)
Net Income (TTM)
-723.32MCNY-107.89M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
14.17%Operating Cash Flow (TTM)
558.39MCNY83.29M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
400.55MCNY59.75M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0100CNYUpdated Sep 19, 2026Trailing Annual Dividend Yield
0.18%vs all stocks
5-Year Average Dividend Yield
1.09%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
7.19MCNYFY2025 · Dec 31, 2025Revenue
623.64MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
236.09MCNYFY2025 · Dec 31, 2025Gross Profit
387.56MCNYFY2025 · Dec 31, 2025Operating Income
-2.65MCNY-395.27K · vs all stocks (USD)
Pre-tax Income
-278.14MCNYFY2025 · Dec 31, 2025Income Tax Expense
70.06MCNYFY2025 · Dec 31, 2025Net Income
-348.21MCNYFY2025 · Dec 31, 2025EBIT
-2.65MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
458.98MCNYFY2025 · Dec 31, 2025Research & Development
115.40MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
119.68MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.53MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.71MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.3400CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.3400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.02BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.02BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-348.21MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.01MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-735.27MCNYFY2025 · Dec 31, 2025Free Cash Flow
-928.24MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
500.37MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-348.21MCNYFY2025 · Dec 31, 2025Other Non-cash Items
278.94KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-14.76MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-372.58MCNYFY2025 · Dec 31, 2025Capital Expenditures
-192.97MCNYFY2025 · Dec 31, 2025Purchase of Investments
-293.43MCNYFY2025 · Dec 31, 2025Sale of Investments
366.06MCNYFY2025 · Dec 31, 2025Other Investing Activity
-18.94MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-139.28MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-17.90MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-17.90MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.03BSharesUpdated Sep 19, 2026Float Shares
629.34MSharesUpdated Sep 19, 2026% Held by Insiders
40.98%vs all stocks
% Held by Institutions
1.01%vs all stocks
Total Cash (MRQ)
1.24BCNY184.30M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.20CNYUpdated Sep 19, 2026Total Debt (MRQ)
0.00CNYvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xCurrent Ratio (MRQ)
7.78xBook Value per Share (MRQ)
4.79CNYUpdated Sep 19, 2026Total Assets
6.07BCNY905.71M · vs all stocks (USD)
Total Current Assets
2.09BCNYFY2025 · Dec 31, 2025Total Liabilities
883.49MCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.98BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
153.91MCNYFY2025 · Dec 31, 2025Total Current Liabilities
729.59MCNYFY2025 · Dec 31, 2025Cash
496.34MCNYFY2025 · Dec 31, 2025Cash Equivalents
23.06MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
519.40MCNYFY2025 · Dec 31, 2025Other Short-term Investments
498.95MCNYFY2025 · Dec 31, 2025Accounts Receivable
80.55MCNYFY2025 · Dec 31, 2025Inventory
681.81MCNYFY2025 · Dec 31, 2025Accounts Payable
95.54MCNYFY2025 · Dec 31, 2025Other Current Liabilities
42.91MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.03BCNYFY2025 · Dec 31, 2025Retained Earnings
3.48BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.19BCNY773.93M · vs all stocks (USD)
52-Week Low
4.81CNYUpdated Sep 19, 202652-Week High
9.40CNYUpdated Sep 19, 202652-Week Change
-22.70%vs all stocks
Beta
-0.1540xvs all stocks
50-Day MA
5.97CNYUpdated Sep 19, 2026200-Day MA
6.53CNYUpdated Sep 19, 2026Avg 10-Day Volume
16.96MSharesUpdated Sep 19, 2026Avg 30-Day Volume
39.16MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
-0.7100CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.64Profit Margin: -1.27
Financial Health
Altman Z-Score 5.09: safe zoneNotable
Altman Z-Score: 5.09
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $59.75M, above the global median of $18.73MNotable
Levered free cash flow (USD): 59,746,159.715Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Chongqing Pharscin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wuhan Keqian Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shouyao Holdings Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kuros Biosciences AG
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
L&C Bio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Candel Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule